It recorded a net loss of $630.8 million. Across the 9 fiscal years shown, revenue shrank from $11.9 million in fiscal 2016 to $9.8 million in fiscal 2024, about 2.4% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
10
-6.4%
|
10
-27.4%
|
14
+41.2%
|
10
+2.7%
|
10
+50.5%
|
7
-47.2%
|
13
-31.4%
|
18
+53.2%
|
12
+171.6%
|
| Cost of revenue |
—
|
—
|
3
-24.5%
|
4
-34.0%
|
7
+79.5%
|
4
-7.1%
|
4
+128.4%
|
2
+15.6%
|
2
-46.0%
|
3
+13.0%
|
2
+95.4%
|
| Gross profit |
—
|
—
|
6
+6.5%
|
6
-21.8%
|
8
+19.4%
|
7
+9.2%
|
6
+22.7%
|
5
-55.8%
|
11
-28.8%
|
15
+63.7%
|
9
+202.3%
|
| Research and development |
—
|
—
|
0
+23.5%
|
0
-80.5%
|
0
+295.5%
|
0
-84.6%
|
0
+54.9%
|
0
-29.0%
|
0
-36.8%
|
0
-70.1%
|
1
-76.1%
|
| Selling, general and administrative |
15
+98.8%
|
8
-33.5%
|
11
+12.4%
|
10
-33.6%
|
15
-0.3%
|
15
+26.7%
|
12
-14.0%
|
14
-24.4%
|
19
-16.7%
|
22
+17.3%
|
19
+5.3%
|
| Operating income |
22
+372.2%
|
-8
-14.4%
|
-7
-79.9%
|
-4
+71.5%
|
-14
-62.7%
|
-9
-37.9%
|
-6
+31.6%
|
-9
-19.4%
|
-8
-7.7%
|
-7
+33.4%
|
-11
+48.0%
|
| Pretax income |
—
|
—
|
—
|
-10
+9.1%
|
-11
-82.1%
|
-6
+47.2%
|
-11
-14.3%
|
-10
-47.6%
|
-7
+11.6%
|
-7
+43.7%
|
-13
+30.7%
|
| Income tax |
6
|
0
|
0
|
—
|
0
|
0
-100.0%
|
0
-16.7%
|
0
+50.0%
|
0
+33.3%
|
0
+50.0%
|
0
+0.0%
|
| Net income |
-74
-2367.6%
|
-631
-8632.9%
|
-7
+25.1%
|
-10
+9.1%
|
-11
-82.1%
|
-6
+47.2%
|
-11
-14.3%
|
-10
-47.6%
|
-7
+11.6%
|
-7
+43.7%
|
-13
|
| Basic EPS |
-0.56
-114.4%
|
-108.39
-754.8%
|
-12.68
+90.9%
|
-139.14
-1277.6%
|
-10.10
-92.0%
|
-5.26
-1596.8%
|
-0.31
+35.4%
|
-0.48
-23.1%
|
-0.39
+18.7%
|
-0.48
+65.7%
|
-1.40
+79.5%
|
| Diluted EPS |
—
|
—
|
—
|
—
|
—
|
—
|
-0.31
+35.4%
|
-0.48
-4.3%
|
-0.46
+4.2%
|
-0.48
+65.7%
|
-1.40
+79.5%
|
| Weighted average shares, basic |
131
+15664.9%
|
6
+757.1%
|
1
+465.8%
|
0
-92.5%
|
2
+29.1%
|
1
-96.4%
|
35
+62.1%
|
22
+27.9%
|
17
+10.4%
|
15
+62.9%
|
9
+237.9%
|
| Weighted average shares, diluted |
—
|
—
|
—
|
—
|
—
|
—
|
35
+62.1%
|
22
+26.9%
|
17
+11.3%
|
15
+62.9%
|
9
+237.9%
|
| Other measures | |||||||||||
| Depreciation and amortization |
—
|
—
|
0
-21.6%
|
0
|
—
|
0
|
—
|
—
|
—
|
—
|
—
|
| EBITDA |
—
|
—
|
-7
-81.2%
|
-4
|
—
|
-9
|
—
|
—
|
—
|
—
|
—
|
| Margins | |||||||||||
| Gross margin |
—
|
—
|
66.26%
|
58.19%
|
54.02%
|
63.85%
|
60.04%
|
73.66%
|
87.98%
|
84.73%
|
79.29%
|
| Operating margin |
—
|
—
|
-75.44%
|
-39.23%
|
-100.09%
|
-86.85%
|
-64.69%
|
-142.45%
|
-62.93%
|
-40.10%
|
-92.31%
|
| Pretax margin |
—
|
—
|
—
|
-92.20%
|
-73.65%
|
-57.08%
|
-111.07%
|
-146.26%
|
-52.29%
|
-40.59%
|
-110.52%
|
| Profit margin |
—
|
—
|
-73.85%
|
-92.20%
|
-73.65%
|
-57.08%
|
-111.12%
|
-146.36%
|
-52.33%
|
-40.61%
|
-110.54%
|
| EBITDA margin |
—
|
—
|
-75.03%
|
-38.75%
|
—
|
-86.27%
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Finance Services (SIC 6199)
- Listed as
- SDEV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- West Palm Beach, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1389545
- Former names
- NovaBay Pharmaceuticals, Inc. (until Mar 23, 2026)
Other Finance Services companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.